FALVELLA, FELICIA STEFANIA
FALVELLA, FELICIA STEFANIA
Universita' degli Studi di MILANO
A comprehensive appraisal of laboratory biochemistry tests as major predictors of COVID-19 severity
2020 E. Aloisio, M. Chibireva, L. Serafini, S. Pasqualetti, F.S. Falvella, A. Dolci, M. Panteghini
An unexpectedly prolonged severe hyperbilirubinemia in a patient with pre-existing hepatitis A: A role of genetic predisposition?
2018 F.S. Falvella, E. Angeli, L. Cordier, E. Clementi, M. Panteghini
Atazanavir-induced severe episodes of kidney stones in an HIV-1-infected subject characterized by a CYP3A poor metabolizer phenotype
2014 S. Rusconi, R. Gagliardini, F.S. Falvella, D. Cattaneo, V. Di Cristo, A. De Luca, M. Fabbiani, E. Clementi, M. Galli, S. Di Giambenedetto
Deferasirox-induced serious adverse reaction in a pediatric patient : pharmacokinetic and pharmacogenetic analysis
2016 M. Marano, G. Bottaro, B. Goffredo, F. Stoppa, M. Pisani, A.M. Marinaro, F. Deodato, C. Dionisi Vici, E. Clementi, F.S. Falvella
Definition of the Immune Parameters Related to COVID-19 Severity
2022 S. Birindelli, M.S. Tarkowski, M. Gallucci, M. Schiuma, A. Covizzi, P. Lewkowicz, E. Aloisio, F.S. Falvella, A. Dolci, A. Riva, M. Galli, M. Panteghini
DPD and UGT1A1 deficiency in colorectal cancer patients receiving triplet chemotherapy with fluoropyrimidines, oxaliplatin and irinotecan
2015 F.S. Falvella, S. Cheli, A. Martinetti, C. Mazzali, R. Iacovelli, C. Maggi, M. Gariboldi, M.A. Pierotti, M. Di Bartolomeo, E. Sottotetti, R. Mennitto, I. Bossi, F. de Braud, E. Clementi, F. Pietrantonio
HLA-B*57: 01 testing : Care in interpreting the quality of different genotyping methods
2017 F.S. Falvella, S. Cheli, E. Clementi
Is a pharmacogenomic panel useful to estimate the risk of oxaliplatin-related neurotoxicity in colorectal cancer patients?
2019 F. Nichetti, F.S. Falvella, R. Miceli, S. Cheli, R. Gaetano, G. Fucà, G. Infante, A. Martinetti, C. Antoniotti, A. Falcone, M. Di Bartolomeo, C. Cremolini, F. de Braud, F. Pietrantonio
Is COVID-19 severity associated with anti-spike antibody duration? Data from the ARCOVID prospective observational study
2021 F. Borgonovo, M. Passerini, M. Piscaglia, V. Morena, A. Giacomelli, L. Oreni, G. Dedivitiis, A. Lupo, S. Falvella, M.V. Cossu, A.F. Capetti
ITPA and SLC29A1 Genotyping for the Prediction of Ribavirin Dose Reduction in Anti-HCV Triple Therapy with Protease Inhibitors
2015 A. Lombardi, S. Landonio, C. Magni, S. Cheli, C. Mazzali, M.U. Mondelli, G. Rizzardini, E. Clementi, F.S. Falvella
Levofloxacin-induced seizures in a patient without predisposing risk factors : the impact of pharmacogenetics
2013 C. Gervasoni, D. Cattaneo, F.S. Falvella, P. Vitiello, S. Cheli, L. Milazzo, E. Clementi, A. Riva
Renal function in HIV/HBV co-infected and HBV mono-infected patients on a long-term treatment with tenofovir in real life setting
2017 L. Milazzo, C. Gervasoni, F.S. Falvella, D. Cattaneo, C. Mazzali, P. Ronzi, F. Binda, S. Cheli, S. Sollima, S. Antinori
SLC29A1 polymorphism and prediction of anaemia severity in patients with chronic hepatitis C receiving triple therapy with telaprevir
2015 L. Milazzo, A.M. Peri, C. Mazzali, C. Magni, E. Calvi, A. De Nicolò, E. Clementi, S. Cheli, A. D'Avolio, S. Antinori, F.S. Falvella
The role of Toll-like receptor 4 polymorphisms in vaccine immune response
2016 P. Pellegrino, F.S. Falvella, S. Cheli, C. Perrotta, E. Clementi, S. Radice
Undetected toxicity risk in pharmacogenetic testing for dihydropyrimidine dehydrogenase
2015 F.S. Falvella, M. Caporale, S. Cheli, A. Martinetti, R. Berenato, C. Maggi, M. Niger, F. Ricchini, I. Bossi, M. Di Bartolomeo, E. Sottotetti, F.F. Bernardi, F. de Braud, E. Clementi, F. Pietrantonio